News Wire

For the second consecutive year, total payments to care for individuals living with Alzheimer’s or other dementias are projected to surpass a quarter of a trillion dollars ($277 billion), which includes an increase of nearly $20 billion over last year, according to data reported in the Alzheimer’s Association 2018 Alzheimer’s Disease Facts and Figures report.

Positive topline results have been reported from the completed phase 3 studies of the investigational agent HTX-011 (Heron Therapeutics) in patients undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2).

François de Brantes, whose payment reform organization merged with the Altarum institute about a year ago, has been fired. His last day was Friday.

A pregnant woman who becomes ill from the Zika virus faces a 7% chance that her child will be born with birth defects, and that risk jumps to nearly 13% if she becomes ill during the first trimester, a study conducted in French territories in the Americas has concluded.

A new treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) that would cut the number of infusions needed each year by three-quarters fared well in a pivotal phase 3 study, the developer announced.

Smoking is associated with increased risk of hearing loss, according to a study of more than 50,000 participants over eight years.

The FDA has granted a breakthrough therapy designation for erdafitinib (Janssen Pharmaceuticals) in the treatment of urothelial cancer, an often-aggressive disease with a grim prognosis that is seen most frequently in the bladder. It’s the sixth most common type of cancer in the U.S.

An analysis commissioned by a pharmaceutical industry trade group found that hospitals participating in the 340B Drug Discount Program have higher per-patient outpatient pharmacy costs than their non-340B counterparts––indicating patients at 340B hospitals are prescribed more medicines, more expensive medicines, or both.

GlaxoSmithKline (GSK) has won a further reprieve for its blockbuster lung drug Advair (fluticasone propionate and salmeterol inhalation powder) after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug, Reuters reports.

Urgent action must be taken to address the dramatic rise of cancer drug prices and to better align prices with value, according to a report released by the President's Cancer Panel.

African-American men lowered their high blood pressure to healthy levels when aided by a pharmacist and their barber, according to a study from the Smidt Heart Institute. The findings were published in the New England Journal of Medicine and presented as a late-breaking clinical trial at the American College of Cardiology's 67th Annual Scientific Session in Orlando.

Generic antiplatelet drugs seem to work as well as a brand-name drug for heart patients, according to research published in Circulation: Cardiovascular Quality and Outcomes.

A large study of cardiovascular events in gout patients taking one of two medications to prevent excess build-up of uric acid has found that one of the drugs, febuxostat (Uloric, Takeda), increased the risk of death for those with heart disease compared with the other drug, allopurinol.

Alirocumab injection (Praluent, Regeneron Pharmaceuticals/Sanofi) reduced the risk of major cardiac events by 15% among patients who had suffered heart attacks and other coronary events in the ODYSSEY OUTCOMES trial. The two companies have announced that they are willing to offer price breaks on the costly medication.

Disappointing results in the phase 3 RESULT trial have led Anthera Pharmaceuticals, Inc., to discontinue development of its drug candidate Sollpura for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis.